Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802892 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
A Phase 1 study of Transplantation, Stem Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01802892 is a Phase 1 study of Transplantation, Stem Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01802892, a Phase 1 study of Transplantation, Stem Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study aims to evaluate the impact of 5 days oral administration of ronacaleret 100 miligram (mg) and 400 mg on changes in circulating CD34+ cells, when ronacaleret is followed by the administration of a single dose of plerixafor in healthy human volunteers. This single centre adaptive design study will be carried out in 2 parts. The part A will evaluate the change in peripheral circulating CD34+ cells in response to two different 5 day regimens of ronacaleret (100 mg or 400 mg once daily), given in conjunction with a single dose of plerixafor (0.24 mg/kilogram \[kg\]) sub-cutaneously (SC) on the evening of the final days dosing approximately 12 hours before collection of CD34+ cells on day 6. Subjects (5 each) will be assigned to either one of the ronacaleret arms, in an open fashion. Comparisons will be made in the change from baseline to end of treatment peripheral CD34+ cell counts. Part A will be conducted in two cohorts with 5 subjects being enrolled into each of the 2 treatment arms making up the first cohort. Cohort 2 will involve up to 5 further subjects being enrolled into each treatment arm. The structure of part B will be finalized following a review of data generated in part A. The total study duration of Part A for each subject including the screening, treatment and follow-up periods will be approximately 7 weeks.
Conditions Studied
Interventions
- DRUG Plerixafor
- DRUG Ronacaleret 100 mg
- DRUG Ronacaleret 400 mg
Study Locations (1)
Kansas
- GSK Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2013-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01802892
The ClinicalTrials.gov registry entry for NCT01802892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplantation, Stem Cell appearing as the primary indexed condition, and to 3 interventions - of which Plerixafor is the first listed.
NCT01802892 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01802892 about?
NCT01802892 is a clinical study titled "Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)". The present study aims to evaluate the impact of 5 days oral administration of ronacaleret 100 miligram (mg) and 400 mg on changes in circulating CD34+ cells, when ronacaleret is followed by the administration of a single dose of plerixafor in healthy human volunteers. This single centre adaptive d...
What is the current status of trial NCT01802892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2012-11-02. Estimated completion is 2013-04-02.
What conditions does trial NCT01802892 study?
This clinical trial studies the following conditions: Transplantation, Stem Cell.
What interventions are being tested in trial NCT01802892?
The interventions under investigation include: Plerixafor (DRUG), Ronacaleret 100 mg (DRUG), Ronacaleret 400 mg (DRUG).
Who is sponsoring clinical trial NCT01802892?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01802892 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.